AbbVie Header AbbVie Header

X

Find the latest Drugs in Development and Pipeline Prospector News of Janssen Ortho LLC.

Client Virtual Booth
  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Johnson & Johnson Innovative Medicine
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
1125 Trenton-Harbourton Road, P.O. Box 200, Titusville, NJ 08560
Telephone
Telephone
+1 8007755514
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Rybrevant (amivantamab) is an EGFR-MET bispecific antibody, being evaluated in combination with chemotherapy for the treatment of previously untreated EGFR exon 20 insertion mutation-positive NSCLC.


Lead Product(s): Amivantamab,Pemetrexed,Carboplatin

Therapeutic Area: Oncology Product Name: Rybrevant

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 28, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.


Lead Product(s): Amivantamab,Lazertinib

Therapeutic Area: Oncology Product Name: Rybrevant

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

JNJ-80202135 (nipocalimab) is an investigational, high-affinity, fully human monoclonal antibody that aims to selectively block FcRn. It is being evaluated for the treatment of Sjögren's disease.


Lead Product(s): Nipocalimab

Therapeutic Area: Immunology Product Name: JNJ-80202135

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Imbruvica (ibrutinib) is a USFDA approved Bruton’s tyrosine kinase inhibitor. It is being evaluated in combination with venetoclax for the treatment of chronic lymphocytic leukemia.


Lead Product(s): Ibrutinib,Venetoclax

Therapeutic Area: Oncology Product Name: Imbruvica

Highest Development Status: Phase IIProduct Type: Small molecule

Recipient: Pharmacyclics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Imbruvica (ibrutinib) is a USFDA approved BTK inhibitor. It is being evaluated for the treatment of chronic lymphocytic leukemia in patients 65 Years or older.


Lead Product(s): Ibrutinib

Therapeutic Area: Oncology Product Name: Imbruvica

Highest Development Status: Phase IIIProduct Type: Small molecule

Recipient: Pharmacyclics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Xencor has regained its rights of XmAb13676 (plamotamab) from Janssen, a tumor-targeted antibody, which is being evaluated for the treatment of elapsed/refractory non-Hodgkin lymphoma.


Lead Product(s): Plamotamab

Therapeutic Area: Oncology Product Name: XmAb13676

Highest Development Status: Phase IProduct Type: Large molecule

Recipient: Xencor

Deal Size: $1,313.0 million Upfront Cash: $100.0 million

Deal Type: Termination June 13, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Carvykti (ciltacabtagene autoleucel) is a FDA approved BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of relapsed/refractory multiple myeloma in adults.


Lead Product(s): Ciltacabtagene Autoleucel

Therapeutic Area: Oncology Product Name: Carvykti

Highest Development Status: ApprovedProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of exon 19 deletions or L858R mutated NSCLC.


Lead Product(s): Amivantamab,Lazertinib,Carboplatin

Therapeutic Area: Oncology Product Name: Rybrevant

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Darzalex (daratumumab) is a CD38 inhibitor, currently it is being evaluated in combination with bortezomib, lenalidomide, dexamethasone for the treatment of multiple myeloma.


Lead Product(s): Daratumumab,Bortezomib,Lenalidomide

Therapeutic Area: Oncology Product Name: Darzalex

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.


Lead Product(s): Amivantamab,Lazertinib

Therapeutic Area: Oncology Product Name: Rybrevant

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 31, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY